Phase I/II study to evaluate consolidative hypofractionated radiation therapy for boosting the residual primary disease in combination with durvalumab after definitive chemoradiation therapy for stage III non-small cell lung cancer (NSCLC): study protocol for a prospective trial.

"Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-304/coif). C.Z. received grand funding from AstraZeneca, Inc., clinical trial research funding from BioMiMetix, and travel support from GTMedical Technologies. C.Z. reports a US Provisional patent (63/164,215) issued which is unrelated to the current study. A.K.G. reports Grants to his institution from Veterans Health Administration Office of Research and Development, Merck, TAB Biosciences, NEKTAR Therapeutics, Mirati Therapeutics, IOVANCE Therapeutics, Apexigen; Royalties from Oxford University Press; Consulting fees from AstraZeneca, Flagship Biosciences, G1 Therapeutics, Jazz Pharmaceuticals, Cardinal Health, Mirati Therapeutics, Beigene Ltd., Sanofi Genzyme, Blueprint Medicines, Regeneron Pharmaceuticals; Honoraria for lectures from MedLearning Group and Plexus Communications; DSMB for YmAbs Therapeutics; Leadership roles in Academic and Community Cancer Research United (ACCRU) and A Breath of Hope for Lung Cancer (ABOHLC); Receipt of drugs to the institution from Takeda Pharmaceuticals and Chimerx. C.W. reports funding from Chi Zhang’s grant (PI Astra Zeneca Pharmaceuticals IIT Grant; UNMC project number MEDI4736). The other authors have no conflicts of interest to declare."

"Funding: The study is funded by AstraZeneca ."

"Registration: Clinicaltrials.gov: NCT04748419."